Skip to content

Explore the efficacy and and safety of single-center randomized controlled polypropylene mesh auxiliary plus adipose-derived mesenchymal stem cells in the treatment of pelvic organ prolapse

Explore the efficacy and and safety of single-center randomized controlled polypropylene mesh auxiliary plus adipose-derived mesenchymal stem cells in the treatment of pelvic organ prolapse

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15006045
Enrollment
Unknown
Registered
2015-03-06
Start date
2015-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic organ prolapse

Interventions

One:polypropylene mesh
Two:polypropylene mesh auxiliary plus adipose-derived mesenchymal stem cells

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. To aged 55 to 65 year-old woman, suffering from the symptoms of prolapse or vault prolapse POP-Q III-IV stage, suitable for surgery, the researchers agreed to participate and signed informed consent; 2. stress incontinence need simultaneously transvaginal mid urethral sling (TVT-O).

Exclusion criteria

Exclusion criteria: Generally poor, difficult to tolerate serious medical complications of laparoscopic surgery; 1. a history of patch application pelvic organ prolapse surgery; 2. reproductive system, urinary system, or with active systemic infection, surgery can be postponed until after the infection cleared; 3. coagulation disorders or are receiving therapeutic anticoagulation drugs; 4. had previously received chemotherapy or pelvic radiotherapy; 5. impact of bladder or bowel function systemic diseases (such as Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury, etc.); 6. patients with chronic pelvic pain; 7. poorly controlled chronic cough; 8. BMI=30; 9. The researchers believe there may be other medical or mental illness can not be with the completion of the investigator.

Design outcomes

Primary

MeasureTime frame
effectiveness;

Secondary

MeasureTime frame
safety;

Contacts

Public ContactZhu Lan
zhu_julie@vip.sina.com+86 13911714696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026